TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Variation of MyMD1 concentration in blood plasma as a function of time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline QTcF and QTcB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients with Changes in clinical laboratory values - Serum Chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Smoking Lapse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Rate of Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Local and systemic immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Best overall response rate per RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC_ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmin_ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax_ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of attempts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in ICH volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of clinical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: recommended Phase 2 dose (RPTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Temperatures in Target Range During Transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Selective Reminding Test (SRT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: neural and cognitive consequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Mean 24-hour Ambulatory Blood Pressure Monitoring Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of L3-4 vertebral interspace identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic Mean Gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Daily Step Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Transferred to Intensive Care Unit (ICU)
Endpoint domain: Mortality/survival
Primary endpoint: Clinically or microbiologically proven typhoid infection
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung ultrasound grading for pneumonia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of cleared IMA root lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Total number of cleared lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Absence of fusion of peripheral anterior and posterior capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Urinary tract infection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cmax - Maximum Observed Concentration - Venlafaxine in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Venlafaxine in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Venlafaxine in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial oxygen pressure (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Non-detectable serum HCV-RNA and normal serum ALT activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sexual functions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Uptake of 64Cu-plerixafor in target lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Expression of TLR2 and TLR4 in peripheral blood monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lower limb mechanical axis deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Joint orientation angles deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Central venous catheter established within first 2 puncture attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Psoriasis Area and Severity Index (PASI) Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Hypoglycemic Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of GSK189075
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urine glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in patient's skin appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence and Severity of Ovarian Hyperstimulation Syndrome (OHSS)
Endpoint domain: Adverse events/effects
Primary endpoint: compliance to nutrition therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Change in Daily Reflective Total Nasal Symptom Scores (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Attempts for Successful Central Venous Cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom From RA and RV Lead-related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Development of emotional psychopathology of the child
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parents' Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Wound Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Motor Evoked Potentials (MEP) Amplitude Measure in milliVolt (mV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in H-Reflex /M-Wave (Hmax/Mmax) Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Usage of opioid analgetics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physical Health Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Geometric mean concentration of antibody against Hepatitis E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Ramulu's sustained reading test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Semen parameters pre-cancer treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semen parameters post-cancer treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number, frequency, duration, and relation of toxicity events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to reach peak serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum anti-PTx antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum anti-diphtheria antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum anti-tetanus antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient Distress score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Muscular strength (hand grip) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscular strength (peak of torque) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscular strength (total work) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postural Balance (weight transfer) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postural Balance (sway velocity) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of subjects with drug-related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of Neuro-Visual Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mental health symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Idiographic problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tumor sensitivity to doxorubicin vs paclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in emotional distress measured as anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Treated With Antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: sustained response rate after treatment discontinuation
Endpoint domain: Mortality/survival
Primary endpoint: Maintenance Success for Total Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of local anaesthetic block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of 89Zr-ipilimumab in tumor lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Exhibiting an in Vivo Resting CD4+ T Cell- Associated HIV RNA Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With a Significant in Vivo Response in Resting Cell Infection and HIV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cognitive endpoints as assessed by the Neurobehavioral Evaluation System (NES-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvasculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Macro vasculature (carotid intima media thickness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate variability (24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of E7820 With Irinotecan
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Formoterol Plasma Drug Concentration (Cmax) at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Formoterol Plasma Drug Concentration (Cmax) Following a Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of anti-emetic in treating postoperative nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % days of 'heavy drinking'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Gastric Ulcer Who Had One or More Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Duodenal Ulcer Who Had One or More Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Reflux Esophagitis Who Had One or More Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of intracranial aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients diagnosed with angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptability of MMR
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in WOMAC pain subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percent time pH > 4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: FDGmax SUV % change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual and Reproductive Health Knowledge Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Contraceptive intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Communication with provider
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Stable performance in daily life
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Phone call - Sound Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of cause of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients who have MDD remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to MDD remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete IUD expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Tumour Size Change at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Quantitatively Balanced and Unbalanced Knees
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients with CD8/FOXP3 ratio conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Parent satisfaction with virtual presence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Operating room provider satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Operating room induction nurse satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ceramic crown fracture
Endpoint domain: Adverse events/effects
Primary endpoint: Tissue Oxygen Tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in gut microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnostic accuracy of 68Ga-PSMA PET/MR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall of 20% FEV1 from baseline values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient Pain Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady State Area Under the Drug Concentration Time Curve (AUC(0-12))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTD of vorinostat based on incidence of DLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreases body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevention of weight regain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radiographic response in the size of the hemangioblastoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of IPMN patients with relatives with pancreatic cancer or IPMN
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of total energy intake as carbohydrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of complex carbohydrate intake from total carbohydrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Otoacoustic Emissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-invasive EEG recording
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ramsay score scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: L-PFS (Local Progression-Free Survival)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of T lymphocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of natural killer (NK) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of sPD-1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Paraneoplastic neoplastic disease antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytotoxic T Lymphocyte activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probable Percentage of Participants Remaining Alive at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: percent liver fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change In Spontaneity Domain of PAIRS scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total incidence of all related SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Self-Care Maintenance (HF patient)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-Care Management (HF patient)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-Care Confidence (HF patient)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Death from biliary tract carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Change of fatigue intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Annual incidence of first-ever-stroke
Endpoint domain: Mortality/survival
Primary endpoint: changes in organoleptic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of investigational product (TAA-T)
Endpoint domain: Adverse events/effects
Primary endpoint: Suicide severity
Endpoint domain: Adverse events/effects
Primary endpoint: SCI evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants losing at least 5% of initial body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body Constitution Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Questionnaire for Children (Kid-KINDL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The Child and Adolescent Scale of Participation (CASP)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Patients with Xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: utilization of medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urethral Shape at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urethral Motion at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urethral Shape at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urethral Motion at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical safety labs from predose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vital signs (blood pressure and heart rate) from predose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: electrocardiogram (ECG) intervals, ECG rhythm, and ECG axis from predose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pharmacokinetic parameters following single dose administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes